Cryo-Cell reports Q3 EPS 8c vs. 6c last year

Reports Q3 revenue $7.87M vs. $7.68M last year. David Portnoy, Co-CEO, commented, “We remain focused on driving forward the potential clinical use of cord blood and cord tissue cells to treat a variety of neurological indications, including cerebral palsy, autism, and hypoxic ischemic encephalopathy. We are currently funding the completion of a Phase 2 autism trial and expect to begin a Phase 3 CP trial in the first half of 2024. These clinical trials and the R&D investments associated with a commercial grade, stem cell laboratory are currently anticipated to be the major use of the company’s cash flows over the next several years.”